Immune Design Corp. (NASDAQ:IMDZ) shares were up 2.3% during trading on Monday . The company traded as high as $7.24 and last traded at $7.04, with a volume of 71,626 shares trading hands. The stock had previously closed at $6.88.

A number of research analysts recently commented on IMDZ shares. Leerink Swann restated a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Wells Fargo & Co. restated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Jefferies Group reiterated a “buy” rating and set a $20.00 price objective on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Cowen and Company reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. Finally, Zacks Investment Research lowered Immune Design Corp. from a “buy” rating to a “hold” rating in a research note on Friday, May 13th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $24.00.

The company’s market capitalization is $141.07 million. The stock has a 50-day moving average of $9.30 and a 200-day moving average of $11.63.

Immune Design Corp. (NASDAQ:IMDZ) last issued its earnings results on Tuesday, May 10th. The company reported ($0.61) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. Equities research analysts anticipate that Immune Design Corp. will post ($2.70) EPS for the current fiscal year.

Other hedge funds and institutional investors have modified their holdings of the company. Oxford Asset Management acquired a new position in shares of Immune Design Corp. during the fourth quarter valued at approximately $1,166,000. Jennison Associates increased its position in shares of Immune Design Corp. by 0.6% in the third quarter. Jennison Associates now owns 202,683 shares of the company’s stock valued at $2,473,000 after buying an additional 1,224 shares in the last quarter. Finally, Jennison Associates LLC increased its position in shares of Immune Design Corp. by 0.4% in the fourth quarter. Jennison Associates LLC now owns 203,452 shares of the company’s stock valued at $4,085,000 after buying an additional 769 shares in the last quarter.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.